Redefining treatment in COPD: New directions in bronchodilator therapy

Treatments in Respiratory Medicine

Volumn 3, Issue 2, 2004, Pages 89-95

  Lipson, David A ^a  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOPHYLLINE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; FENOTEROL; FLUTICASONE PROPIONATE; FORMOTEROL; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 8; IPRATROPIUM BROMIDE; LEUKOTRIENE B4 RECEPTOR ANTAGONIST; LEVALBUTEROL; LONG ACTING DRUG; METHYLXANTHINE DERIVATIVE; MUSCARINIC RECEPTOR; OXITROPIUM BROMIDE; OXYGEN; PHOSPHODIESTERASE IV INHIBITOR; PIRBUTEROL; PLACEBO; PNEUMOCOCCUS VACCINE; PROTEINASE INHIBITOR; SALBUTAMOL; SALMETEROL; SHORT ACTING DRUG; TERBUTALINE; THEOPHYLLINE; TIOTROPIUM BROMIDE; UNINDEXED DRUG;

AIRFLOW; AIRWAY RESISTANCE; ARTIFICIAL VENTILATION; AWARENESS; BRONCHODILATATION; CARDIOVASCULAR DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONSENSUS DEVELOPMENT; DIAGNOSTIC PROCEDURE; DISABILITY; DISEASE SEVERITY; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG ADMINISTRATION ROUTE; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG HALF LIFE; DRUG MECHANISM; DRUG POTENTIATION; DRUG SAFETY; DYSPNEA; EXERCISE; FORCED EXPIRATORY VOLUME; HEALTH CARE ORGANIZATION; HEART SUPRAVENTRICULAR ARRHYTHMIA; HUMAN; HYPOKALEMIA; LUNG INFLATION; LUNG SURGERY; MEDICAL EXPERT; NUTRITIONAL HEALTH; PATIENT CARE; PATIENT COUNSELING; POPULATION RESEARCH; PRACTICE GUIDELINE; PRIORITY JOURNAL; PSYCHOSOCIAL CARE; PUBLIC HEALTH; QUALITY OF LIFE; REHABILITATION; REVIEW; SMOKING CESSATION; SURVIVAL; SYMPTOMATOLOGY; TACHYCARDIA; TACHYPHYLAXIS; TIME; TREATMENT PLANNING; TREMOR; UNITED STATES; WORLD HEALTH ORGANIZATION; XEROSTOMIA;

ALGORITHMS; BRONCHODILATOR AGENTS; CHOLINERGIC ANTAGONISTS; EXERCISE TOLERANCE; HUMANS; IPRATROPIUM; PNEUMONECTOMY; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RECEPTORS, ADRENERGIC, BETA-2; XANTHINES;

EID: 2342577516     PISSN: 11763450     EISSN: None     Source Type: Journal    
DOI: 10.2165/00151829-200403020-00003     Document Type: Review

References (73)

1. National Heart, Lung, and Blood Institute. Morbidity & mortality: chartbook on cardiovascular, lung, and blood diseases. Bethesda (MD): US Department of Health and Human Services, Public Health Service, NIH, 1998
2. Benson V, Marano MA. Current estimates from the National Health Interview Survey, 1995. Vital Health Star 10 1998; 199: 1-428
3. Centers for Disease Control and Prevention. Achievements in Public Health, 1900-1999: decline in deaths from heart disease and stroke: United States, 1900-1999. MMWR Morb Mortal Wkly Rep 1999; 48: 649-56
4. Murray CJ, Lopez AD. Regional patterns of disability-free life expectancy and disability-adjusted life expectancy: Global Burden of Disease Study. Lancet 1997; 349: 1347-52
5. Murray CJ, Lopez AD. Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study. Lancet 1997; 349: 1436-42
6. Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet 1997; 349: 1498-504
7. Pauwels RA, Buist AS, Calverley PMA, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease: NHLBI/WHO global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease (GOLD) workshop summary. Am J Respir Crit Care Med 2001; 163: 1256-76. 2003 update [online]. Available from URL: http://www.goldcopd.com [Accessed 2004 Feb 2]
8. O'Donnell DE, Lam M, Webb KA. Measurement of symptoms, lung hyperinflation, and endurance during exercise in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998; 158: 1557-65
9. Belman MJ, Botnick WC, Shin JW. Inhaled bronchodilators reduce dynamic hyperinflation during exercise in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1996; 153 (3): 967-75
10. Hay JG, Stone P, Carter J, et al. Bronchodilator reversibility, exercise performance and breathlessness in stable chronic obstructive pulmonary disease. Eur Respir J 1992; 5 (6): 659-64
11. American Thoracic Society Statement: standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1995; 152 Suppl. 5: 77-121
12. Vathenen AS, Britton JR, Ebden P, et al. High-dose inhaled albuterol in severe chronic airflow limitation. Am Rev Respir Dis 1988; 138: 850-5
13. Ferguson GT, Cherniak RM. Management of chronic obstructive pulmonary disease. N Engl J Med 1993; 328: 1017-22
14. COMBIVENT Inhalation Aerosol Study Group. In chronic obstructive pulmonary disease, a combination of ipratropium and albuterol is more effective than either agent alone: an 85-day multicenter trial. Chest 1994; 105 (5): 1411-9
15. van Noord JA, de Munck DR, Bantje TA, et al. Long-term treatment of chronic obstructive pulmonary disease with salmeterol and the additive effect of ipratropium. Eur Respir J 2000; 15: 878-85
16. Sin DD, Tu JV. Inhaled corticosteroids and the risk of mortality and readmission in elderly patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 164: 580-4
17. The Lung Health Study Research Group. Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. N Engl J Med 2000; 343: 1902-9
18. Burge PS, Calverley PM, Jones PW, et al. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ 2000; 320 (7245): 1297-303
19. Hattotuwa KL, Gizycki MJ, Ansari TW, et al. The effects of inhaled fluticasone on airway inflammation in chronic obstructive pulmonary disease: a double-blind, placebo-controlled biopsy study. Am J Respir Crit Care Med 2002; 165 (12): 1592-6
20. Mahler DA, Wire P, Horstman D, et al. Effectiveness of fluticasone propionate and salmeterol combination delivered via the diskus device in the treatment of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2002; 166: 1084-91
21. Nocturnal Oxygen Therapy Trial Group. Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease. Ann Intern Med 1980; 93: 391-8
22. Medical Research Council Working Party. Long-term domiciliary oxygen therapy in chronic hypoxic cor pulmonale complicating chronic bronchitis and emphysema. Lancet 1981; I: 681-6
23. Tarpy SP, Celli BR. Long-term oxygen therapy. N Engl J Med 1995; 333: 710-4
24. ACCP/AACVPR Pulmonary Rehabilitation Guidelines Panel. Pulmonary rehabilitation: Joint ACCP/AACVPR evidence-based guidelines. Chest 1997; 112 (5): 1363-96
25. Celli B. Is pulmonary rehabilitation an effective treatment for chronic obstructive pulmonary disease? Yes. Am J Respir Crit Care Med 1997; 155: 781-3
26. Fishman AP. Pulmonary rehabilitation research: NIH workshop summary. Am J Respir Crit Care Med 1994; 149: 825-33
27. American Thoracic Society. Official statement: pulmonary rehabilitation - 1999. Am J Respir Crit Care Med 1999; 159: 1666-82
28. Cooper JD, Patterson GA, Sundaresan RS, et al. Results of 150 consecutive bilateral lung volume reduction procedures in patients with severe emphysema. J Thorac Cardiovasc Surg 1996; 112: 1319-30
29. Criner GJ, Cordova FC, Furukawa S, et al. Prospective randomized trial comparing bilateral lung volume reduction surgery to pulmonary rehabilitation in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999; 160: 2018-27
30. Flaherty KR, Kazerooni EA, Curtis JL, et Al. Short-term and long-term outcomes after bilateral lung volume reduction surgery: prediction by quantitative CT. Chest 2001; 119: 1337-46
31. Geddes D, Davies M, Koyama H, et al. Effect of lung-volume-reduction surgery in patients with severe emphysema. N Engl J Med 2000; 343: 239-45
32. Sciurba FC, Rogers RM, Keenan RJ, et al. Improvement in pulmonary function and elastic recoil after lung-reduction surgery for diffuse emphysema. N Engl J Med 1996; 334: 1095-9
33. Kotloff RM, Hansen-Flaschen J, Lipson DA, et al. Apical perfusion fraction as a predictor of short term functional outcome following bilateral lung volume reduction surgery. Chest 2001; 120 (5): 1609-15
34. Arcasoy SM, Kotloff RM. Medical progress: lung transplantation. N Engl J Med 1999; 340: 1081-91
35. British Thoracic Society. BTS guidelines for the management of chronic obstructive pulmonary disease: the COPD guidelines group of the standards care committee of the BTS. Thorax 1997; 52 Suppl. 5: 1-28
36. Jenkins SC, Heaton RW, Fulton TJ, et al. Comparison of domiciliary nebulized salbutamol and salbutamol from a metered-dose inhaler in stable chronic airflow limitation. Chest 1987; 91: 804-7
37. O'Donnell DE, Lam M, Webb KA. Measurements of symptoms, lung hyperinflation, and endurance during exercise in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998; 158: 1557-65
38. Belman MJ, Botnick WC, Shin JW. Inhaled bronchodilators reduce dynamic hyperinflation during exercise in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1996; 153: 967-75
39. Guyatt GH, Townsend M, Pugsley SO, et al. Bronchodilators in chronic airflow limitation: effects on airway function, exercise capacity, and quality of life. Am Rev Respir Dis 1987; 135: 1069-74
40. Nelson HS. β-Adrenergic bronchodilators. N Engl J Med 1995; 333: 499-506
41. Barnes PJ. State of the art: β-Adrenergic receptors and their regulation. Am J Respir Crit Care Med 1995; 152: 838-60
42. 2 agonists. Thorax 1996; 51: 1051-6
43. Barnes PJ. Beta-adrenoceptors on smooth muscle, nerves and inflammatory cells. Life Sci 1993; 52 (26): 2101-9
44. Giannini D, Bacci E, Dente FL, et al. Inhaled beclomethasone dipropionate reverts tolerance to the protective effect of salmeterol on allergen challenge. Chest 1999; 115 (3): 629-34
45. 2 agonists. Thorax 1998; 53: 558-62
46. Hay JG, Stone P, Carter J, et al. Bronchodilator reversibility, exercise performance and breathlessness in stable chronic obstructive pulmonary disease. Eur Respir J 1992; 5 (6): 659-64
47. Mahler DA, Donohue JF, Barbee RA, et al. Efficacy of salmeterol xinafoate in the treatment of COPD. Chest 1999; 115 (4): 957-65
48. Blosser SA, Maxwell SL, Reeves-Hoche MK, et al. Is an anticholinergic agent superior to a beta 2-agonist in improving dyspnea and exercise limitation in COPD. Chest 1995; 108 (3): 730-5
49. Berger R, Smith D. Effect of inhaled metaproterenol on exercise performance in patients with stable 'fixed' airway obstruction. Am Rev Respir Dis 1988; 138 (3): 624-9
50. Iversen ET, Sorensen T, Heckscher T, et al. Effect of terbutaline on exercise capacity and pulmonary function in patients with chronic obstructive pulmonary disease. Lung 1999; 177 (4): 263-71
51. Mahler DA, Donohue JF, Barbee RA, et al. Efficacy of salmeterol xinafoate in the treatment of COPD. Chest 1999; 115: 957-65
52. Dowling RB, Johnson M, Cole PJ, et al. Effect of salmeterol on Haemophilus influenzae infection of respiratory mucosa in vitro. Eur Respir J 1998; 11 (1): 86-90
53. Mak JC, Haddad EB, Buckley NJ, et al. Visualization of muscarinic M4 mRNA and M4 receptor subtype in rabbit lung. Life Sci 1993; 53 (19): 1501-8
54. Barnes PJ. Muscarinic receptor subtypes in airways. Eur Respir J 1993; 6 (3): 328-31
55. Barnes PJ. Muscarinic receptor subtypes in airways. Life Sci 1993; 52: 521-7
56. Barries PJ, Haddad EB, Rousell J. Regulation of muscarinic M2 receptors. Life Sci 1997; 60: 1015-21
57. Casaburi R, Mahler DA, Jones PW, et al. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J 2002; 19 (2): 217-24
58. Donohue JF, van Noord JA, Bateman ED, et al. A 6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol. Chest 2002; 122 (1): 47-55
59. Vincken W, van Noord JA, Greefhorst AP, et al. Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium: Dutch/Belgian Tiotropium Study Group. Eur Respir J 2002; 19 (2): 209-16
60. Anthonisen NR, Connett JE, Kiley JP, et al. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rite of decline of FEV1: the Lung Health Study. JAMA 1994; 272 (19): 1497-505
61. Ferguson GT. Update on pharmacologic therapy for chronic obstructive pulmonary disease. In: Rochester CL, editor. Clinics in chest, medicine. Philadelphia (PA): WB Saunders Company, 2000: 723-38
62. Rennard SI, Serby CW, Ghafouri M, et al. Extended therapy with ipratropium is associated with improved lung function in patients with COPD: a retrospective analysis of data from seven clinical trials. Chest 1996 Jul; 110 (1): 62-70
63. Anthonisen NR, Connett JE, Enright PL, et al. Hospitalizations and mortality in the Lung Health Study. Am J Respir Crit Care Med 2002; 166: 333-9
64. Ghafouri MA, Patil KD, et al. Sputum changes associated with the use of ipratropium bromide. Chest 1984; 86: 387-93
65. Martin RJ, Bartelson BL, Smith P, et al. Effect of ipratropium bromide treatment on oxygen saturation and sleep quality in COPD. Chest 1999; 115 (5): 1338-45
66. Karpel JP. Bronchodilator responses to anticholinergic and beta-adrenergic agents in acute and stable COPD. Chest 1991; 99 (4): 871-6
67. Braun SR, Levy SF. Comparison of ipratropium bromide and albuterol in chronic obstructive pulmonary disease: a three-center study. Am J Med 1991; 91: 28S-32S
68. Dorinsky PM, Reisner C, Ferguson GT, et al. The combination of ipratropium and albuterol optimizes pulmonary function reversibility testing in patients with COPD. Chest 1999; 115 (4): 966-71
69. Spence DP, Hay JG, Carter J, et al. Oxygen desaturation and breathlessness during corridor walking in chronic obstructive pulmonary disease: effect of oxitropium bromide. Thorax 1993; 48: 1145-50
70. Mahler DA, Matthay RA, Snyder PE, et al. Sustained-release theophylline reduces dyspnea in nonreversible obstructive airway disease. Am Rev Respir Dis 1985; 131: 22-5
71. Eaton ML, MacDonald FM, Church TR, et al. Effects of theophylline on breathlessness and exercise tolerance in patients with chronic airflow obstruction. Chest 1982; 82: 538-42
72. Dullinger D, Kronenberg R, Niewoehner DE. Efficacy of inhaled metaproterenol and orally-administered theophylline in patients with chronic airflow obstruction. Chest 1986; 89: 171-3
73. Tsukino M, Nishimura K, Ikeda A, et al. Effects of theophylline and ipratropium bromide on exercise performance in patients with stable chronic obstructive pulmonary disease. Thorax 1998; 53 (4): 269-73